Skip to main content

Axial Spondyloarthritis

14
Pipeline Programs
17
Companies
21
Clinical Trials
3 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
8
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
11100%
+ 19 programs with unclassified modality

On Market (2)

Approved therapies currently available

AbbVie
HUMIRAApproved
adalimumab
AbbVie
2002
258M Part D
Eli Lilly and Company
TALTZApproved
ixekizumab
Eli Lilly and Company
Interleukin-17A Antagonist [EPC]injection2016

Competitive Landscape

15 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
4 programs
2
1
AdalimumabPhase 4Monoclonal Antibody1 trial
AdalimumabPhase 3Monoclonal Antibody
adalimumabPhase 3Monoclonal Antibody1 trial
Active Supervised TrainingN/A1 trial
Active Trials
NCT03258814Terminated17Est. Sep 2018
NCT01808118Completed673Est. Apr 2017
NCT02897115Terminated22Est. Dec 2017
Sandoz
SandozAustria - Kundl
4 programs
1
1
Secukinumab 150 milligram [Cosentyx]Phase 41 trial
Secukinumab/Adalimumab-BiosimilarPhase 31 trial
SmartwatchN/A1 trial
secukinumabN/AMonoclonal Antibody1 trial
Active Trials
NCT06807853Recruiting50Est. Nov 2025
NCT05677542Completed758Est. Dec 2021
NCT03906136Completed304Est. Sep 2022
+1 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
IxekizumabPHASE_3Monoclonal Antibody
MSD
MSDIreland - Ballydine
3 programs
1
GolimumabPhase 3Monoclonal Antibody
MRE review for evidence of axSpA in SIJsN/A
TreatmentN/A
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
3 programs
1
GolimumabPhase 3Monoclonal Antibody1 trial
MRE review for evidence of axSpA in SIJsN/A1 trial
TreatmentN/A1 trial
Active Trials
NCT03817983Completed259Est. Aug 2020
NCT02011386Completed53Est. Feb 2017
NCT03270501Completed64Est. Dec 2023
Biocad
BiocadRussia - St. Petersburg
2 programs
1
1
anti-TRBV9 monoclonal antibody infusionsPhase 31 trial
anti-TRBV9 monoclonal antibody, low dosePhase 21 trial
Active Trials
NCT05445076Active Not Recruiting250Est. Jun 2027
NCT06333210Active Not Recruiting421Est. Feb 2028
Prevail Therapeutics
2 programs
2
IxekizumabPhase 3Monoclonal Antibody1 trial
IxekizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT03129100Completed773Est. May 2021
NCT02757352Completed303Est. May 2019
Sunshine Biopharma
Sunshine BiopharmaQC - Varennes
1 program
1
608Phase 21 trial
Active Trials
NCT06222671Recruiting180Est. Nov 2025
Merck & Co.
Merck & Co.RAHWAY, NJ
3 programs
MRE review for evidence of axSpA in SIJsN/A
TreatmentN/A
GolimumabPHASE_3Monoclonal Antibody
UCB Pharma
UCB PharmaBelgium - Brussels
2 programs
BimekizumabPHASE_3Monoclonal Antibody1 trial
Certolizumab PegolPHASE_31 trial
Active Trials
NCT04436640Active Not Recruiting508Est. Aug 2026
NCT02552212Completed317Est. May 2020
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
Humidified Forest OilsN/A1 trial
Active Trials
NCT06072859Completed10Est. Mar 2024
Novartis
NovartisBASEL, Switzerland
1 program
SmartwatchN/A
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
To withdraw NSAIDs therapyN/A1 trial
Active Trials
NCT03425812Recruiting140Est. Dec 2028
Labcorp
LabcorpBURLINGTON, NC
1 program
biological disease-modifying antirheumatic drugsN/A1 trial
Active Trials
NCT04973787Unknown90Est. Jan 2022
XBiotech
XBiotechAUSTIN, TX
1 program
NatrunixPHASE_21 trial
Active Trials
NCT06526377Not Yet Recruiting60Est. Apr 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
SandozSecukinumab 150 milligram [Cosentyx]
AbbVieAdalimumab
Biocadanti-TRBV9 monoclonal antibody infusions
UCB PharmaBimekizumab
SandozSecukinumab/Adalimumab-Biosimilar
Sharp TherapeuticsGolimumab
Prevail TherapeuticsIxekizumab
Prevail TherapeuticsIxekizumab
UCB PharmaCertolizumab Pegol
AbbVieadalimumab
XBiotechNatrunix
Sunshine Biopharma608
Biocadanti-TRBV9 monoclonal antibody, low dose
SandozSmartwatch
Oregon TherapeuticsHumidified Forest Oils

Showing 15 of 21 trials with date data

Clinical Trials (21)

Total enrollment: 5,340 patients across 21 trials

NCT03639740SandozSecukinumab 150 milligram [Cosentyx]

Treat-to-target With Secukinumab in Axial Spondyloarthritis

Start: Jan 2019Est. completion: Feb 202188 patients
Phase 4Unknown
NCT02897115AbbVieAdalimumab

A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment

Start: Sep 2016Est. completion: Dec 201722 patients
Phase 4Terminated
NCT06333210Biocadanti-TRBV9 monoclonal antibody infusions

Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)

Start: Dec 2023Est. completion: Feb 2028421 patients
Phase 3Active Not Recruiting
NCT04436640UCB PharmaBimekizumab

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

Start: Jun 2020Est. completion: Aug 2026508 patients
Phase 3Active Not Recruiting
NCT03906136SandozSecukinumab/Adalimumab-Biosimilar

AScalate: Treat-to-target in Axial Spondyloarthritis

Start: Jun 2019Est. completion: Sep 2022304 patients
Phase 3Completed
NCT03270501Sharp TherapeuticsGolimumab

Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation

Start: Nov 2017Est. completion: Dec 202364 patients
Phase 3Completed
NCT03129100Prevail TherapeuticsIxekizumab

A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis

Start: May 2017Est. completion: May 2021773 patients
Phase 3Completed
NCT02757352Prevail TherapeuticsIxekizumab

A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis

Start: Aug 2016Est. completion: May 2019303 patients
Phase 3Completed
NCT02552212UCB PharmaCertolizumab Pegol

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

Start: Sep 2015Est. completion: May 2020317 patients
Phase 3Completed
NCT01808118AbbVieadalimumab

Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis

Start: Apr 2013Est. completion: Apr 2017673 patients
Phase 3Completed
NCT06526377XBiotechNatrunix

Natrunix in HLA-B27 Positive Subjects With Axial Spondyloarthritis

Start: Aug 2026Est. completion: Apr 202760 patients
Phase 2Not Yet Recruiting
NCT06222671Sunshine Biopharma608

A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)

Start: Mar 2024Est. completion: Nov 2025180 patients
Phase 2Recruiting
NCT05445076Biocadanti-TRBV9 monoclonal antibody, low dose

Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis

Start: Apr 2022Est. completion: Jun 2027250 patients
Phase 2Active Not Recruiting
NCT06807853SandozSmartwatch

A LONGITUDINAL OBSERVATIONAL STUDY to EVALUATE the EFFICACY of MOVEMENT and IMPLEMENT CONCRETE MOVEMENT RECOMMENDATIONS with the HELP of MOBILITY TRACKING with SMARTWATCHES in SUBJECTS with AXIAL SPONDYLOARTHRITIS

Start: Apr 2024Est. completion: Nov 202550 patients
N/ARecruiting
NCT06072859Oregon TherapeuticsHumidified Forest Oils

The Impact of Simulated Forest Immersion Therapy on Pain and Anxiety in Patients Axial Spondyloarthritis (axSpA)

Start: Sep 2023Est. completion: Mar 202410 patients
N/ACompleted
NCT05677542Sandozsecukinumab

Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study

Start: Jun 2021Est. completion: Dec 2021758 patients
N/ACompleted
NCT04973787Labcorpbiological disease-modifying antirheumatic drugs

The Role of Microbiome on Biological Therapy Efficacy in axSpA and RA

Start: Aug 2020Est. completion: Jan 202290 patients
N/AUnknown
NCT03817983Sharp TherapeuticsMRE review for evidence of axSpA in SIJs

MRE as a Screening Tool for axSpA in IBD

Start: Mar 2019Est. completion: Aug 2020259 patients
N/ACompleted
NCT03425812UNION therapeuticsTo withdraw NSAIDs therapy

Effects of Nonsteroidal Anti-Inflammatory Drugs in Recurrence of Spondyloarthritis Patients After Remission

Start: Feb 2018Est. completion: Dec 2028140 patients
N/ARecruiting
NCT03258814AbbVieActive Supervised Training

A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis (axSpA)

Start: Dec 2017Est. completion: Sep 201817 patients
N/ATerminated
NCT02011386Sharp TherapeuticsTreatment

Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis

Start: Feb 2013Est. completion: Feb 201753 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 5,340 patients
17 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.